HC Wainwright Reaffirms “Buy” Rating for BiomX (NYSEAMERICAN:PHGE)

HC Wainwright reissued their buy rating on shares of BiomX (NYSEAMERICAN:PHGE) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for BiomX’s Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.18) EPS.

BiomX Stock Performance

PHGE stock opened at $0.5468 on Wednesday. BiomX has a fifty-two week low of $0.34 and a fifty-two week high of $1.6196. The firm has a 50-day moving average price of $0.46. The company has a market capitalization of $14.51 million, a P/E ratio of -0.40 and a beta of 1.42.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).